Navigation Links
Certain Breast Cancer Drugs Linked With Heart Risks in Older Women
Date:12/9/2010

By Kathleen Doheny
HealthDay Reporter

THURSDAY, Dec. 9 (HealthDay News) -- Long-term use of aromatase inhibitors, drugs often prescribed to breast cancer patients, may increase the risk of heart problems for postmenopausal women, according to a Canadian researcher.

''There have always been suspicions," said Dr. Eitan Amir, senior fellow at Princess Margaret Hospital in Toronto, who is scheduled to present the findings this week at the San Antonio Breast Cancer Symposium in Texas.

In December 2008, the U.S. Food and Drug Administration added a warning label to anastrozole, an aromatase inhibitor marketed as Arimidex, citing a potential increased risk for heart disease.

Amir's team evaluated previously published studies to find out if other aromatase inhibitors also increased the risk of heart disease in postmenopausal women with breast cancer. ''We looked at seven trials which have compared aromatase inhibitors with tamoxifen,'' he said

Aromatase inhibitors, which also include Femara and Aromasin, prevent the production of estrogen, which some cancers need to grow and spread. Tamoxifen, another drug frequently prescribed for breast cancer patients with estrogen-sensitive tumors, blocks the effect of estrogen in breast tissue. Under current guidelines, the two drugs may be used in either order for the several years of treatment typically recommended.

''Overall, there is a 26 percent increased risk in heart events -- heart attack, angina and heart failure -- for women taking aromatase inhibitors for longer duration," which typically means more than three years, Amir said.

''But those are relative statistics, and they can be a bit misleading," he says. A relative risk compares the risk in two different groups of people. Another measure -- absolute risk -- refers to one person's actual risk of developing the disease over a given time period.

In this study, the absolute risk to any one woman taking an aromatase inhibitor was less alarming. "Only 1 percent more got heart disease," Amir said. But the risk among those who already had risk factors for heart disease, such as high blood pressure, was as high as 7 percent.

''Aromatase inhibitors are being given routinely to many [breast cancer] patients," he said. And not everyone gets the same benefit, he said, so treatment should be based not just on breast cancer risk, but on the patient's cardiovascular profile and other health risks, he said.

"If you have heart disease, perhaps you want to avoid aromatase inhibitors," Amir said.

Another option would be to switch from one drug to the other, to avoid staying on aromatase inhibitors long-term, he said.

When he compared women who used aromatase inhibitors first to those who used tamoxifen first, the risk for serious adverse effects was similar. But there was a hint that switching drugs reduced the risk of death from other causes.

Because this study was presented at a medical meeting, the findings should be viewed as preliminary until they are published in a peer-reviewed journal.

Still, the findings are no surprise, said Dr. Julie Gralow, director of breast medical oncology at Seattle Cancer Care Alliance, who reviewed the study results but was not involved in it.

Aromatase inhibitors aren't perfect, she said. Neither is tamoxifen, which has been linked with blood clots, stroke and cataracts.

"For some women maybe tamoxifen is better," said Gralow, who is careful to follow her patients closely and monitor them for any suggestion of heart disease.

As with much of medical practice, decisions must be made on a case-by-case basis, she said.

More information

To learn more about aromatase inhibitors, visit the U.S. National Cancer Institute.

SOURCES: Eitan Amir, M.D., senior fellow, Princess Margaret Hospital, Toronto, Ontario, Canada; Julie Gralow, M.D., director of breast medical oncology and Seattle Cancer Alliance, and professor, oncology division, University of Washington, Seattle, Wash.; San Antonio Breast Cancer Symposium, Dec. 8-12, 2010, San Antonio, Texas


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Certain Formulations of Omega-3s Might Help With Depression
2. Diagnosis uncertainty increases anxiety in patients
3. Women Taking Certain Epilepsy Drugs Can Safely Breast-Feed, Study Suggests
4. Low Vitamin D Linked to Deterioration in Certain Leukemia Patients
5. New Drug, Pradaxa, May Prevent Second Stroke in Certain Heart Patients
6. New Drug Shows Promise Against Certain Lung Cancers
7. Certain cancer therapies success depends on presence of immune cell, Stanford study shows in mice
8. Certain new therapies for age-related eye disease do not appear to increase heart risks
9. A revolutionary new way of reversing certain cancers
10. Bacteria identified that may lead to inflammatory bowel disease in certain individuals
11. Double-Dose Plavix Benefits Certain Patients, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Certain Breast Cancer Drugs Linked With Heart Risks in Older Women
(Date:1/20/2017)... NY (PRWEB) , ... January 20, 2017 , ... ... VW+ 001 and its sugar-free alternative VW+ 002. The drinks have been produced ... with optimal conditions to perform during your workout. , After a successful launch ...
(Date:1/20/2017)... ... January 20, 2017 , ... “I Forgive You”: a fine examination of how God ... is the creation of published author, Stephen Miller, who, for over ten long years has ... to him. Born in Trinidad and Tobago, he has been serving the Lord for over ...
(Date:1/20/2017)... ... , ... “Knowledge is God’s Lighthouse”: a moving and colorful collection of ... the creation of published author, Gene Gaapf, a retired truck driver, and a long-time ... been writing since high school and have many different titles,” Gaapf mentions about his ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Management System: an On-demand E-learning system for Clinical and Regulatory education for ... is based on Aerolib`s successful education methodology of Disease Specific Documentation Improvement. ...
(Date:1/19/2017)... ... 19, 2017 , ... This month, the CEO and Clinical Director of Sober ... rehab center in Delray Beach, Florida has been changed from Sober Living Outpatient to ... Philip Seymour Hoffman and Chris Farley are dying from heroin overdoses, but thousands of ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... and Webcast to Follow Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... the fourth quarter of 2016 on Wednesday, February 15, 2017, after ... ... on Wednesday, February 15, 2017, during which management will discuss the ... activities. To participate in the conference call, please dial 1-888-771-4371 (domestic) ...
(Date:1/19/2017)... , Jan. 19, 2017 This report ... current and future scenario of the global market. Large ... opioid consumption. Severe chronic constipation is a major side ... traditional laxatives. Hence, novel targeted therapy has been prescribed ... sufferers, launch of targeted medicines, and growing awareness about ...
(Date:1/19/2017)... BioTherapeutics Inc. ( Stealth ), a clinical-stage biopharmaceutical company ... additions to its senior leadership team: W. Douglas ... Daniel Geffken as interim Chief Financial Officer. In ... has been promoted to Chief Clinical Development Officer. ... Daniel to our management team, as both will be ...
Breaking Medicine Technology: